| Perspective |  |
Open Access |
Restoring Regulatory Fairness and Reclaiming Biomedical Leadership: ALS, Rare Disease Regulation, and the Future of Regenerative Medicine
|
|
|
||
Downloads |
Comments |
Views |
|
Abstract |
|
|
Introduction: ALS and the Crisis of Therapeutic Inertia |
|
|
Regulatory Flexibility: Policy Versus Practice |
|
|
The Strategic Importance of Regenerative Medicine |
|
|
Financial Oversight and the Realities of Innovation |
|
|
Special Protocol Assessments and Scientific Legitimacy |
|
|
Statistical Orthodoxy and the Challenge of Heterogeneous Disease |
|
|
Biomarkers, Accelerated Approval, and Regulatory Consistency |
|
|
Procedural Fairness and Advisory Committee Integrity |
|
|
The ACT for ALS and the Implementation Gap |
|
|
Ethics and the Human Cost of Delay |
|
|
Rebuilding Confidence in Regulatory Leadership |
|
|
Comparative Regulatory Precedents in Rare Disease and Regenerative Medicine |
|
|
Conclusion: A Defining Moment for Rare Disease Innovation |
|
|
References |
Authors
 |
Peter J. Pitts , [email protected] | ||
 Corresponding Author |
|||
| Center for Medicine in the Public Interest; University of Paris School of Medicine | |||
|
Chaim Lebovitz | ||
